Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate

  • Kiromic BioPharma Inc KRBP has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT.
  • Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022. 
  • The IND will seek to evaluate Deltacel in combination with a standard antitumor modality, with the expected beginning of trial activation by year-end. 
  • Related: Why Kiromic Biopharma Shares Are Skyrocketing Today?
  • Kiromic will also pursue INDs for its Procel and Isocel product candidates in combination with a standard antitumor modality in 2023.
  • These three additional IND filings will expand the Company's pipeline to five allogeneic GDT clinical trials and three product candidates.
  • Price Action: KRBP shares are up 14.60% at $0.46 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!